Your AI-Trained Oncology Knowledge Connection!
Hope Cottrill, MD, highlights practice-changing developments in endometrial cancer care, the benefits of local control with radiation in patients with locally aggressive disease, and questions that remain regarding treatment sequencing with immunotherapy.
A phase 1/2 study will assess the safety and efficacy of azeliragon in patients refractory to first-line treatment of metastatic pancreatic cancer.
Alexander Drilon, MD, highlights how the approval of repotrectinib addresses the need for improved therapies for patients who have progressed on a previous TKI and delves into notable neurologic toxicities seen with the agent.
Groundbreaking study opens new avenues for future treatment and diagnosis.
The tumor-infiltrating lymphocyte cell therapy OBX-115 produced responses with no dose-limiting toxicities in heavily pretreated patients with advanced or metastatic melanoma whose who had progressed on anti–PD-1 and anti–CTLA-4 therapy with disease that was primary-resistant to immune checkpoint inhibitor therapy.
Rui-Hua Xu, MD, PhD, and Kohei Shitara, MD, expand on the advantages of targeting CLDN18.2 with zolbetuximab in gastric/GEJ adenocarcinoma and key efficacy data from the GLOW and SPOTLIGHT trials in support of zolbetuximab’s potential FDA approval.
Paul G. Richardson, MD, shares clinical findings and several case studies showcasing the encouraging activity and safety of mezigdomide in patients with relapsed/refractory multiple myeloma.
The FDA has approved enfortumab vedotin in combination with pembrolizumab for patients with locally advanced or metastatic urothelial cancer.
Marijo Bilusic, MD, PhD, highlights key insights about renal cell carcinoma that were presented at the meeting covering considerations on sequencing TKIs, the need for further research to elucidate novel therapies, and the importance of offering clinical trials to all patients with genitourinary malignancies.
The combination of pembrolizumab and lenvatinib failed to produce a statistically significant improvement in progression-free survival and overall survival vs platinum-based chemotherapy with carboplatin and paclitaxel as frontline therapy in patients with advanced or recurrent endometrial cancer whose disease in mismatch repair proficient/not microsatellite instability–high or mismatch repair deficient.
The FDA has granted fast track designation to naporafenib plus trametinib for use as a potential therapeutic option in adult patients with unresectable or metastatic melanoma with an NRAS mutation who progressed on or are intolerant to a PD-1/PD-L1–based regimen.
Treatment with zanubrutinib conferred a PFS benefit vs bendamustine plus rituximab across most biomarker subgroups of patients with treatment-naive chronic lymphocytic leukemia or small lymphocytic lymphoma without del(17p), according to findings from the phase 3 SEQUOIA trial.
The FDA has approved belzutifan (Welireg) for the treatment of patients with advanced renal cell carcinoma (RCC) following a PD-1 or PD-L1 inhibitor and a VEGF TKI.
The majority of patients with relapsed CLL treated with zanubrutinib or ibrutinib in the phase 3 ALPINE study did not acquire a BTK or PLCG2 mutation at the time of disease progression, indicating that these mutations may not be the primary drivers of resistance and relapse in this population.
The combination of RP1 and cemiplimab provided a numerical, but not statistically significant, improvement in response rates vs cemiplimab alone in patients with locally advanced or metastatic cutaneous squamous cell carcinoma, missing the primary end points of the phase 2 CERPASS trial.
Idecabtagene vicleucel has received marketing and manufacturing approval in Japan for its supplemental new drug application in patients with relapsed/refractory multiple myeloma who have received at least 2 prior lines of therapy.
Jaime R. Merchán, MD, discusses the evolution and current role of IO/TKI regimens in advanced RCC; highlights data from the phase 3 CLEAR and KEYNOTE-426 trials supporting the use of pembrolizumab-based regimens in untreated ccRCC; and speculates on how future biomarker-driven research could improve the benefit seen with these combinations in this disease.
The FDA has accepted and granted priority review to the biologics license application seeking the approval of tarlatamab for the treatment of patients with advanced small cell lung cancer.
Physician-scientists from Rutgers Cancer Institute of New Jersey and RWJBarnabas Health will present an extensive array of hematology/oncology data from their clinical research program at the 65th American Society of Hematology Annual Meeting and Exposition, being held in San Diego, California from December 9-12, 2023.
The novel bispecific antibody KN026 and docetaxel elicited responses with an acceptable toxicity profile when administered as neoadjuvant treatment in patients with HER2-positive early or locally advanced breast cancer.
The European Commission has granted marketing authorization to dostarlimab paired with carboplatin and paclitaxel in adults with dMMR/MSI-H primary advanced or recurrent endometrial cancer who are eligible to receive systemic treatment.
The FDA has approved eflornithine (Iwilfin) as a treatment to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma who have achieved at least a partial response to prior multi-agent, multimodality therapy including anti-GD2 immunotherapy.
Responses on the non-covalent BTK inhibitor pirtobrutinib remained high in patients with relapsed chronic lymphocytic leukemia who expressed frequent baseline BTK mutations, according to a genomic analysis of the phase 1/2 BRUIN trial.
Maria Hafez, MD, discusses factors such as HER2 status, lymph node negativity, and risk stratification that influence the selection of adjuvant treatment approaches for patients with early-stage HER2-positive breast cancer and expands on pivotal data that have changed the paradigm.
University of California prostate cancer experts will share clinical insights at the first annual PSMA Conference, “PSMA PET and RLT: Present and Future.”
The presence of mutated SRSF2 in knock-in mouse models of JAK2 V617F–driven myeloproliferative neoplasms reduced the rate of polycythemia and hampered hematopoietic progenitor functions.
Javier Cortés, MD, PhD, expands on the importance of investigating the central nervous system activity of trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases; key efficacy data from the pooled analysis of the agent in the DESTINY-Breast01, -02 and -03 trials; and more.
DZD8586 showcased antitumor activity and favorable safety with limited grade 3 or greater treatment-emergent adverse effects in patients with heavily pretreated B-cell non-Hodgkin lymphoma, according to preliminary findings from a pooled analysis of two ongoing phase 1 trials.
Treatment with asciminib elicited greater efficacy and had a more tolerable safety profile compared with bosutinib for patients chronic myeloid leukemia in chronic phase following treatment with 2 or more TKIs.
The addition of isatuximab-irfc to carfilzomib, lenalidomide, and dexamethasone was well tolerated and elicited a 100% objective response rate in standard- and high-risk, transplant-eligible patients with newly diagnosed multiple myeloma.
